Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo fiscal 1996 sales grow 9%, fueled by OTCs, nutritionals.

This article was originally published in The Tan Sheet

Executive Summary

PERRIGO FY 1996 SALES INCREASE 9% BUOYED BY GROWING NUTRITIONALS BUSINESS and rising OTC drug sales, the private-label manufacturer reported Aug. 14. Sales for the fiscal year ended June 30 rose to $778.1 mil., up from $717.1 mil. in FY 1995. However, net profits for fiscal 1996 slumped, falling 10.3% to $39.8 mil

You may also be interested in...



QUOTED. 28 September 2020. Kyle Sampson.

If President Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsberg, Affordable Care Act coverage could disappear. See what Kyle Sampson, a partner with the Washington, DC law firm King & Spalding said about it here.

Quick Listen: Scrip’s Five Must-Know Things

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip

Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel